Emma de Launay Email

Senior Clinical Trials Manager . Invex Therapeutics

Current Roles

Employees:
4
Revenue:
$620k
About
Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendinâ„¢.
Invex Therapeutics Address
38 Rowland Street
Subiaco, WA
United States
Invex Therapeutics Email